Our strategy uses a natural difference in Stem Cell Factor (SCF), which occurs in a long and a short form. Our lead monoclonal antibody, OpSCF binds and inactivates only the longer form of SCF.
The function of SCF is to stimulate a receptor called c-kit that occurs on a variety of cells. The long form of SCF stimulates c-kit present on immune cells, causing them to produce and release substances that perpetuate inflammation that in the long term manifest as the accumulation of scar tissue, or fibrosis.
c-Kit+ Cells Promote Fibrosis by Producing Pro-Fibrotic Cytokines
Chronic inflammation and fibrosis is a characteristic of a number of diseases, including glomerulonephritis and chronic kidney disease due to diabetes and hypertension, idiopathic pulmonary fibrosis, scleroderma and systemic sclerosis, and severe, steroid-resistant asthma.
A shorter form of SCF stimulates c-kit on cells in the bone marrow that are responsible for making new red blood cells. Because of its design, OpSCF cannot bind to or interfere with these “housekeeping” functions of SCF. High dose safety studies have not shown any adverse effects of OpSCF.
Two Types of SCF with Distinct Structures & Functions
OpSCF has been shown to be effective in numerous laboratory models of chronic inflammation and fibrosis. OpSCF decreases fibrosis, the number of inflammatory cells, and the amount of chronic inflammatory cytokines. OpSCF returns the inflammatory environment back to normal, allowing tissues to heal normally.
MOA of OpSCF in Glomerulonephritis